THE  JENEX  CORPORATION

                           "Prevention Is The Solution"

           Medical Device Company

·         Focused on the research and development of their patented thermal therapy technology.

·         Over $6.5 million invested in intellectual property, research and development of the thermal therapy technology.

·         The intercept^CS Cold Sore Prevention System launch is now under way exclusively with Shoppers Drug Mart in the Canadian market.

 Patented Technology

·         Jenex currently holds patents for the technology in Canada, the United States, Europe and Australia.

intercept^CS

·         intercept^CS is the latest clinically proven application for Jenex’s thermal therapy technology.

·         Received approval from Health Canada’s regulatory Therapeutic Products Programme (TPP) to market intercept^CS, OTC (over-the-counter) for cold sore prevention with the claim: “For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort.  Also helps alleviate the embarrassment that typically is associated with herpes labialis (cold sores) outbreaks.”

·         Jenex’s intercept^CS is the only approved product for the prevention for cold sores.

·          Jenex has now launched  exclusively with Shoppers Drug Mart, Canada’s largest Drug Store Chain.  A national advertising campaign will commence April 15^th.

·         Jenex’s intercept^CS is the only approved product for the prevention of cold sores.

          For further information visit :   

              http://www.interceptcs.com                 

       Significant Market Opportunity

·         Current medical research indicates that 20 to 40% of the population experience recurrent cold sore outbreaks.  In the Canadian market alone, that figure translates from 5 million to as many as 10 million people who suffer recurrent bouts of cold sores.  In the United States these estimates translate to between 40 million and 80 million recurrent cold sore sufferers.

·         Worldwide, the cold sore category represents a multi-billion dollar industry. With appropriate marketing strategies, advertising support and retail distribution, Jenex’s intercept^CS Cold Sore Prevention System has the potential to dominate this large and underdeveloped market.

            Therapik®

·         First product developed from the thermal therapy technology.

·         Therapik® is approved in Canada and the United States as a Class II medical device and has CE approval for Europe with a claim to stop the pain, itch and inflammation caused by insect stings and bites.

                         "Prevention Is The Solution"